 Xinyong Liu Ph.D
Principal Professor of Med. Chem.,
Director of Medicinal Chemistry Institute;
Vice Dean of School of Pharmaceutical Sciences,
Shandong University
CURRENT ADRRESS
Prof. Dr. Xinyong Liu
Department of Medicinal Chemistry
School of of Pharmaceutical Sciences，Shandong University
No.44, Wenhuaxi Road, Jinan, 250012 P.R.China
Tel. 086-531-88380270, 88382005, Fax. 086-531-88382548，E-mail: xinyongl@sdu.edu.cn
SOCIAL APPOINTMENTS
1.Editor of“E-journal Chemistry”(2012-)
2.Editorial Board member of ”Current Medicinal Chemistry” (2010-)
3.Editorial Board Member of “World Journal of Virology (WJV)” (2011-2015)
4.Editorial Board member of “Drug Discoveries & Therapeutics”(2011-)
5. Editorial Board member of “World Journal of Clinical Infectious Diseases”(2011-)
6.Editorial Board member of “World Journal of Pharmacology” (2011-)
7. Editorial Board member of “Virology Discovery” (2012-)
8. Editorial Board member of journal “Interactive Medicinal Chemistry”(2013-)
9. Editorial Board member of“Chinese Journal of Pharmaceuticals” (2011-)
10. Editorial Board member of “Journal of Shandong University(Health Science)”(2011-)
11.Editorial Board member of ”Chinese Journal of Medicinal Chemistry”(2010-)
12. Scientist Enjoying Special Government Allowances of the State Council of China (2011-)
13. Executive Member and Vice general secretary of Shandong Pharmaceutical Association (2012-)
14. Awarded as Shandong Provincial Outstanding Medical Academic Professional (2009-)
15.Executive Member of The Shandong Provincial Health Care Council(2007-)
16. Membership of Medicinal Chemistry Committee of Shandong (2008-).
17. Awarded as Young Talent of Shandong Province in Science and Technology achievements (2004)
18. Awarded as Young Star of Sci and Tech. of Jinan City, Shandong Province (2000).
19. Peer Reviewer for the National Ntural Science Fundation of China(2003-)
20. Peer Reviewer for the Foundation of Istituto Pasteur-Fondazione Cenci Bolognetti, supporting research in the scientific domains typical of the Institut Pasteur in Paris( 2012-)
21.Peer Reviewer for the Health and Medical Research Fund (HMRF) administered by the Food and Health Bureau of the Government of the Hong Kong SAR(2012-)
EDUCATION
Ph.D.2001-2004, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University
M.S. 1988-1991, Deparment of Medicinal Chemistry, Shandong Medical University.
B.S. 1980-1984, College of Pharmacy, Shandong Medical University.
PROFESSIONAL EXPERIENCE
2001-Present, Principal Professor, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University.
1999-2001, Associate Professor, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University.
1997-1999, Visiting Scholar, at Institute of Medicinal Chemistry, Consejo Superior de Investigaciones Cientificas (CSIC) of Espania, Madrid, Spain.
1994-1997, Associate Professor, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong Medical University.
1988-1994, Lecturer, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong Medical University.
TEACHING COURSES
1. For Master students: “Advanced Organic Chemistry”, “Separation and Purification techniques in organic Synthesis”
2. For undergraduates: “Bioorganic Chemistry”, “Organic Synthesis”，“Pharmaceutical English”
RESEARCH INTERSTE
1. Our research work is partly engaged in the rational drug design, synthesis and antiviral evaluation of a variety of molecules that interact with specific enzymes and receptors in viral life cycle (HIV, HBV, HCV, FluV). Presently, (1) in anti-HIV drug research, we are focusing on the design and synthesis of novel non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs), and the new HIV-1 transactivation inhibitors based on HIV-1Tat-TAR interaction in the viral transcription step, as well as the novel multiple ligands (inhibitors) simultaneously targeting at HIV-1 RT and integrase. (2) in anti-HBV drug research, we are focusing on design and synthesis of some novel non-nucleoside (small molecules) inhibitors.(3) in anti-influenza drug research, we are conducting the neuramidinase inhibitors and RNA polymerase inhibitors.
2. Our second ongoing program is synthesis of some natural products from Chinese Traditional Medicine active in cardio/vascular diseases. Presently we are focusing on molecular modification and structure-activity relationships of Ligustrazine derivatives.
3. Drug delivery research on PEGylated small molecular agents.
RESEARCH FOUNDING
1. Design, synthesis and biological evaluation of some novel DAPY derivatives bearing six-membered central heterocycles as potent HIV-1 NNRTIs with improved resistant profiles. National Natural Science Foundation of China. No. 81273354, 2013.01-2016.12
2. Design, synthesis and biological evaluation of Novel HEPT derivatives as HIV-1 No-nucleoside reverse transcriptase inhibitors (NNRTIs). Key Project of International Collaboration project of National Natural Science Foundation of China., No.30910103908; 2010.01-2013.12
3. Preclinical studies of Ligustrazinyl ferulate as potent anti-ischemic agent, State Key projects for science and technology development.(drug candidates branch), No. 2009ZX09103-117, 2009-2010
4. Structure-Based Design and synthesis of Multivalent Ligands against HIV-1 replication. Excellent Young Chinese Foreigner Project of National Natural Science Foundation of China. No.30928031, 2010.01-2012.12
5. Design, synthesis and biological evaluation of substituted thiadiazine derivatives as HIV-1 No-nucleoside reverse transcriptase inhibitors (NNRTIs). National Natural Science Foundation of China. No. 30873133; 2009.1-2011.12
6. Design, synthesis and biological evaluation of pyrrozothiatriazine derivatives as HIV-1 NNRTIs . National Natural Science Foundation of China. (No. 30371686), 2008.1--2010.12.
7. Design, synthesis and biological evaluation of Novel HEPT derivatives as HIV-1 NNRTIs. Key Project of Chinese educational ministry, No.30910103908; 2010.01-2013.12
8. Design, synthesis of novel substituted heterocyle-fused thiatriazine derivatives and their inhibitory activity against HIV-1 reverse transcriptase. PhD supervisor foundation of Chinese educational ministry. (No. 20070422083), 2008.1--2010.12
9. Cerebro/Cardiovascular Drug Research and Development of Novel Ligustrazine Derivatives. Rsearch project of Sci.＆Tech Bureau of Shandong Province (No. 2006GG2202063) 2007.1-2010.1
10. Preparation and pharmacokinatics of HIV-1 reverse transcriptase inhibitor AZT conjugates. Key Project of Sci.＆Tech Bureau of Jnan City (No. 200705100), 2007.10--2010.10
11. Synthesis and Anti-HIV Activity Evaluation of Heterocycle-fused Thiadiazine Derivatives. National Natural Science Foundation of China. (No. 30371686), 2004.1--2006.12
12. Heterocycle-fused Thiadiazine Derivatives: Synthesis and Screening of Novel HIV-1 NNRTIs. Key Project of International Collaboration, Chinese Sci.＆Tech Ministry. (No.2003DF000033) 2004.1-2007.1
REPRESENTATIVES OF RECENT PUBLICATION
2013
Wenjun Li, Peng Zhan, Erik De Clercq, Hongxiang Lou*, Xingyong Liu*. Current Drug research on PEGytion with small molecular agents. Progress in Polymer Science, 2013; 38: 421-444. (IF= 24.1)
Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu*. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Medicinal Research Review, 2013; 33(S1): E1-E72 (IF=10.7)
Yu’ning Song, Peng Zhan,* Dongwei Kang, Xiao Li, Ye Tian, Zhenyu Li, Xuwang Chen, Wenmin Chen, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of novel pyridaziylthioacetamides as potent hiv-1 nnrtis using a structure-based bioisosterism approach. Medicinal Chemistry Communications. 2013; 4(5): 810-816
Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Erik De Clercq, Xinyong Liu*. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Letters in Drug Design & Discovery, 2013; 10(1): 27-34
Yu'ning Song, Peng Zhan, Qingzhu Zhang and Xinyong Liu*. Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry. Current Pharmaceutical Design. 2013; 19(8): 1528-1548
Peng Zhan, Xinyong Liu*. Multivalent agents: a novel concept for anti-HIV drug discovery. Current Medicinal Chemistry, 2013, 20(6): pp. 815-832
Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21(7): 2128-34.
Xuwang Chen, Shufang Ding, Peng Zhan and Xinyong Liu*. Recent Advances of Diaryl Ether Family as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Current Pharmaceutical Design. 2013; 19(15): 2829-2838
Hongfei Chen, Guoning Li, Peng Zhan, Xiuli Guo, Qian Ding, Shouxun Wang and Xinyong Liu*. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Med. Chem. Commun., 2013, 4, 827-832
SUN Sang-Dun, MI Si-Qi, YOU Jing, YU Ji-Liang, HU Song-Qing, LIU Xin-Yong. HQSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors[J]. Acta Phys. Chim. Sin., 2013, 29 (6), 1192-1200
Zhenyu Li, Fang Yu, Lei Cui, Chen Wenmin, Shouxun Wang, Peng Zhan, Xinyong Liu*. Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents. Medicinal Chemistry. accepted
Hongfei Chen; Guoning Li; Qian Ding; Lei Cui; Peng Zhan; Shouxun Wang; Xinyong Liu* Ligustrazine derivatives. Part 8: Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Bioorganic & Medicinal Chemistry Letter, submitted
Peng Zhan, Xiao Li, Diwakar Rai, Erik De Clercq and Xinyong Liu*. Rationally designed multivalent anti-HIV agents. Curr Top Med Chem. Accepted
Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Yuemao Shen and Xinyong Liu*. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry, 2013, 9, 000-000
Tian Ye, Xinyong Liu*. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA-02-13-1571) . Chemical Biology & Drug Design.
Xuwang Chen, Yuanyuan Li, Shufang Ding, Jan Balzarini, Christophe Pannecouque, Erik De Clercq and Xinyong Liu. Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Acceptance of Your Manuscript cmdc.201300130 for ChemMedChem
Liu Huiqing, Xinyong Liu*. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion injury in rat via modulating oxidative stress. Experimental Brain Research, submitted
Chunmin Weia, b,*, Lingjun Konga*, Xinbing Weia, Lin Chena, Xiaoqian Liua, Xiumei Zhanga, Xinyong Liuc, Huiqing Liua **. Pharmacokinetics of a New Tetramethylpyrazine Analogue CXC195 in Rats. Drug Research
2012
Dongyue Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of six representative candidates. Journal of Medicinal Chemistry, 2012, 55 (8), pp 3595–361. (IF= 5.2) (DOI: 10.1021/jm200990c)
Xuwang Chen, Peng Zhan, Xin Liu, Ziheng Cheng, Caicai Meng, Siyuan Shao, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*, Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2012: 20 : 3856–3864
Wenjiun Li, Jingde Wu, Peng Zhan, Yu Chang, Christophe Pannecouque, Erik De Clercq & Xinyong Liu*. Synthesis, drug release and anti-HIV Activity of a series of PEGylated zidovudine conjugates. International Journal of Biological Macromolecules. 2012;50(4): 974-980
Xuwang Chen, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012; 51: 60-66
Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Structure-based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry Letters. 2012; 22: 7155–7162
Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of Novel 2-(3-(2-Chlorophenyl) pyrazin-2-ylthio)-N-arylacetamides As Potent HIV-1 Inhibitors Using a Structure-Based Bioisosterism Approach. Bioorganic & Medicinal Chemistry, 2012, Volume 20, Issue 23, Pages 6795–6802
Xiao Li, Peng Zhan*, Hong Liu, Dongyue Li, Liu Wang , Xuwang Chen, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl) thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic & Medicinal Chemistry. 2012; 20: 5527-5536
Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu* Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and Biological Investigation of Thiazolylthioacetamides Derivatives as A Novel Class of Potential Antiviral Agents. Archives of Pharmacal Research, 2012;Vol 35, No 6, 975-986,
Lijuan Deng, Xiuli Guo, Li Zhai, Yuning Song, Hongfei Chen, Peng Zhan, Jingde Wu, Xinyong Liu*. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel Ligustrazine-based stilbene derivatives as potential cerebrocardiac vascular agents. Chemical Biology & Drug Design. 2012 May ; 79 ( 5 ): 731-739
(DOI: 10.1111/j.1747-0285.2012.01332.x)
Wenwen Chen, Peng Zhan, Erik De Clercq and Xinyong Liu*. Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors. Current Pharmaceutical Design, 2012; 18(1): 4165-4186
Zhenyu Li, Peng Zhan, Lieve Naesens, Evelien Vanderlinden, Ailin Liu, Guanhua Du, Erik De Clercq and Xinyong Liu*. Synthesis and preliminary biological evaluation of 5-substituted-2-(4- substituted phenyl) benzoxazoles as a novel class of influenza virus A inhibitors. Chemical Biology & Drug Design. 2012; 79 ( 6 ): 1018-24
Ye Tian, Peng Zhan, Diwakar Rai, Jiyan Zhang, Erik De Clercq and Xinyong Liu*. Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 NNRTIs. Current Medicinal Chemistry, 2012; 19(13): 2026-2037.
Wenmin Chen, Peng Zhan, Jingde Wu, Zhenyu Li and Xinyong Liu*. The Development of HEPT-type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Its Implications for DABO Family. Current Pharmaceutical Design, 2012, 18, 4165-4186
Xiaofei Jiang, Peng Zhan, Xinyong Liu * & Erik De Clercq. Synthesis and Anti-HIV Activity Evaluation of 2-(5-(Naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides Derivatives. Lat. Am. J. Pharm. 2012; 31 (5): 751-755
Zhenyu Li, Fang Yu, Lei Cui, Peng Zhan, Shouxun Wang* and Xinyong Liu*. Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazine acylguanidine derivatives as potential cerebrocardiac vascular agents. Medicinal Chemistry. 2012 Jun 25. 2012;8(5):928-33.
Xiao Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. The HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (Part V): Capravirine and Its Analogues. Current Medicinal Chemistry, 2012; 19 ( 36): Pp.6138-6149
Peng Zhan, Dongyue Li, Junyi Li, Xuwang Chen and Xinyong Liu,* Benzimidazole (Benzimidazolone) Heterocycle as A Privileged Scaffold in Antiviral Agents. Mini-Review in Organic Chemistry, 2012, 9, 397-410
Zhai L, Zhang P, Sun RY, Liu XY, Liu WG, Guo XL.Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol Rep. 2012, Nov;63(6):1469-80.
2011
Zhang Jing, Zhan Peng, Wu Jingde, Li Zhenyu, Jiang Yan, Ge Weiying, Pannecouque C, De Clercq E, Liu Xinyong*. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2011; 19: 4366–4376
Mingyan Yu, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. ChemMedChem 2011; 6(5): 826–833
Mingyan Yu, Xinyong Liu*, Ailin Liu, Guanhua Du, Lieve Naesens, Evelien Vanderlinden, Erik De Clercq. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. Chemical Biology & Drug Design, 2011, 78(4): 596–602
Peng Zhan, Xuwang Chen, Dongyue Li, Wenwen Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Arylazolylthioacetanilide part 8. Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamides As Potent HIV-1 Inhibitors. European Journal of Medicinal Chemistry. 2011; 46 : 5039-5045
Zhan Peng, Li Dongyue, Chen Xuwang, Liu Xinyong*, De Clercq Erik. Functional Roles of Azoles Motif in Anti-HIV Agents. Current Medicinal Chemistry, 2011; 18(1): 29-46
Hongfei Chen, Peng Zhan, Xinyong Liu*. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. European Journal of Medicinal Chemistry. 2011;46: 5609-5615
Zhan Peng, Liu Xinyong*. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin. Ther. Patents (2011) ; 21(5):1-80
Jiang Yan, Liu Xinyong*, De Clercq Erik. New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle. Current Medicinal Chemistry, 2011; 18(1): 16-28
Mingyan Yu, Erkang Fan, Jingde Wu and Xinyong Liu*. Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Current Medicinal Chemistry, 2011, 18(16): 2376-2385
Zhang Jing, Ge Weiying, Zhan Peng, De Clercq E, Liu Xinyong*. Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication. Curr Med Chem. 2011; 18(17): 2649-2654.
Xuwang Chen, Peng Zhan, Dongyue Li, Erik De Clercq and Xinyong Liu*. Recent Advances in DAPYs and Related Analogues as HIV-1 NNRTIs. Current Medicinal Chemistry, 2011, 18, 359-376
Zhenyu. Li, Peng. Zhan and Xinyong Liu*. 1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents. Mini-Reviews in Medicinal Chemistry, 2011, 11: 1130-1142
Peng Zhan, Xuwang Chen, Xinyong Liu*, Christophe Pannecouque, Lieve Naesens, Erik De Clercq, Ailin Liu, Guanhua Du. Thiazolylthioacetamides as a Novel Class of Potential Antiviral Agents. Antiviral Research, Volume 90, Issue 2, May 2011, Page A67.
Wenjun Li, Peng Zhan, Jingde Wu, Yu Chang, Christophe Pannecouque, Erik De Clercq, Xinyong Liu.* Synthesis, Influence of Polymer Molecular Weight on Drug Release and Anti-HIV Activity of PEGylated AZT Conjugates. Antiviral Research, Volume 90, Issue 2, May 2011, Page A37.
Peng Zhan, Renzhang Yan, Xinyong Liu,*, Christophe Pannecouque, Myriam Witvrouw , Erik De Clercq, Maria Teresa Molina, Salvador Vega. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-2H,4H-pyrazolo[4,5-e] [1,2,4]thiadiazine derivatives. Drug Discoveries & Therapeutics. 2011; 5(6):279-285.（2012.01.17出刊）
Hu Song-Qing, Mi Si-Qi, Jia Xiao-Lin, Fan Cheng-Cheng, Chen Sheng-Hui, Zhang Jun, Liu Xin-Yong*. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors. Chemical Journal Of Chinese Universities. 2011, Vol. 32 Issue (10) :2402-2409
Yu-Ning Song, Xiu-Li Guo, Bei-Bei Zheng, Xin-Yong Liu, Xue Dong, Lu-Gang Yu, Yan-Na Cheng. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Toxicol. Vitro. 2011; vol. 25, no. 4, pp. 937-943,
2010
Wenjun Li, Yu Chang, Peng Zhan, Na Zhang, Xinyong Liu,*Christophe Pannecouque, and Erik De Clercq. Synthesis, In Vitro and In Vivo Release Kinetics, and Anti-HIV Activity of A Sustained-Release Prodrug (mPEG-AZT) of 3’-Azido-3’-deoxythymidine (AZT, Zidovudine). ChemMedChem 2010; 5: 1893-1898.
Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole Thioacetanilides. Part 2. Synthesis and Biological Evaluation of a New Series of 2-(4-(3,4-dichlorophenyl)-1,2,3-Thiadiazol-5-ylthio)Acetamides as Anti-HIV-1 inhibitors. Chemistry & Biodiversity. 2010; 7: 1717-1726
Yang Ou, Xue Dong, Xin-Yong Liu, Xian-Chao Cheng, Yan-Na Cheng, Lu-Gang Yu, and Xiu-Li Guo*. Mechanism of Tetramethylpyrazine Analogue CXC195 Inhibition of Hydrogen Peroxide-Induced Apoptosis in Human Endothelial Cells. Biol. Pharm. Bull. 2010; 33(3): 432-438
Ou Y, Guo XL, Zhai L, Liu XY, Cheng YN. TMPDP, a tetramethylpyrazine derivative, protects vascular endothelial cells from oxidation damage by hydrogen peroxide. Pharmazie. 2010 Oct; 65(10):755-9.
Peng Zhan, Hongbing Liu, Xinyong Liu*, Yan Wang, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq. Synthesis and anti-HIV activity evaluation of novel N1-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research. 2010; 19:652–663
Hongfei Chen, Xinyong Liu*, Peng Zhan and Erik De Clercq. TSG101: a Novel Anti-HIV-1 Drug Target. Current Medicinal Chemistry . 2010; 17(8): 750-758
Peng Zhan, Xinyong Liu*, Erik De Clercq. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Current Medicinal Chemistry, 2010; 17(6): 495-503
Peng Zhan, Xuemei Jiang, Xinyong Liu*. Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-nucleoside HBV Inhibitors. Mini-Reviews in Medicinal Chemistry. 2010 Feb;10(2):161-70.
Peng Zhan, Zhenyu Li, Xinyong Liu*. Cosalane and Related Analogues: A Unique Class of Anti-HIV Agents. Mini-Reviews in Medicinal Chemistry, 2010, 10, 966-976
Zhan Peng, Li Wenjun, Chen Hongfei and Liu Xinyong*.Targeting Protein-Protein Interactions: A Promising Avenue of Anti-HIV Drug Discovery. Current Medicinal Chemistry, 2010; 17(6): 495-503
2009
Peng Zhan, Xinyong Liu*, Zhenyu Li, Zengjun Fang, Zhong Li, Defeng Wang, Christophe Pannecouque, Erik De Clercq. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorganic & Medicinal Chemistry, 2009; 17(16): 5920-5927. (15 August 2009).
Mingyan Yu, Xinyong Liu*, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonyl methylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry, 2009;17: 7749–7754
Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation Bioorg Med Chem. 2009; 17(16): 5733-6146
Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem. 2009; 17(16): 5775-5781.
Xinyong Liu*, Peng Zhan, Christophe Pannecouque, Erik De Clercq. Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIS. Antiviral Research, Volume 82, Issue 2, May 2009, Pages A44-A45
Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5- ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009; 44 : 4648–4653
Xian-Chao Cheng, Xin-Yong Liu*, Wen-Fang Xu, Xiu-Li Guo Ning Zhang, Yuning Song Ligustrazine derivatives part 31: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents. Bioorganic & Medicinal Chemistry. 2009; 17: 3018–3024
Yuan Cao, Xinyong Liu* and Erik De Clercq. Cessation of HIV-1 Transcription by Inhibiting Regulatory Protein Rev-Mediated RNA Transport. Current HIV Research, 2009, 7(1):, 101-108
Yu Mingyan, Liu Xinyong* and Erik De Clercq. NF-κB: The Inducible Factors of HIV-1 Transcription and their Inhibitors. Mini-Reviews in Medicinal Chemistry, 2009, 9(1): 60-69
Jiyan Zhang, Xinyong Liu* and Erik De Clercq. Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors. Mini-Reviews in Medicinal Chemistry. 2009; Volume 9(4): April, 510-518.
Yan Wang, Xin-yong Liu* and Erik De Clercq. Role of the HIV-1 Positive Elongation Factor P-TEFb and Inhibitors Thereof. Mini-Reviews in Medicinal Chemistry, 2009, 9(3): 379-385
Peng Zhan and Xinyong Liu*. Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm. Curr Pharm Des. 2009; 36(15): 1893-1917
Peng Zhan, Zhenyu Li, Xinyong Liu* Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs. Mini-Reviews in Medicinal Chemistry, 2009, 9(8): 1014-1023
Peng Zhan, Xinyong Liu* and Zhanyu Li. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Current Medicinal Chemistry, 2009; 16(22): 2876-2889. (August 2009)
Peng Zhan, Xinyong Liu*, Christophe Pannecouque, Erik De Clercq. Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009; 16(29): 3903-3917.
2008
Peng Zhan, Xinyong Liu*, Yuan Cao, Yan Wang, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett. 2008; Oct 15;18(20):5368-71.
Peng Zhan, Xinyong Liu* and Erik De Clercq. Recent Advances in Antiviral Activity of Benzo/Heterothiadiazine Dioxide Derivatives. Current Medicinal Chemistry, 2008; 15(15): 1529-1540.
Yongqiang Lin, Xinyong Liu,* Renzhang Yan, Jin Li, Christophe Pannecouque, Myriam Witvrouw and Erik De Clercq* Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides (TTDDs). Bioorganic & Medicinal Chemistry, 2008; 16 (1): 157–163
Xinyong Liu,* Ren-zhang Yan, Yan Wang, Peng Zhan, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq, Maria Teresa Molina and Salvador Vega. Synthesis and Anti-HIV Activity Evaluation of Novel 2,4-Disubstituted 7-Methyl-1,1,3-trioxo-2H,4H-Pyrazolo[4,5-e] [1,2,4]thiadiazines. Arch.Pharmazie, 2008; 341(4): 216-222
Fang Yu, Xinyong Liu,* Peng Zhan and Erik De Clercq. Recent Advances in the Research of HIV-1 RNase H Inhibitors. Mini-Reviews in Medicinal Chemistry, 2008, Nov; 8(12):1243-51
Xinyong Liu* , Peng Zhan, Renzhang Yan, Yongqiang Lin, Jin Li,Christophe Pannecouque and Erik De Clercq. Design, Synthesis and Antiviral Evaluation of Novel Heterocyclic Compounds as HIV-1 NNRTIs. Drug Discov Ther 2008;2: 25-28
2007
Xian-Chao Cheng, Xin-Yong Liu,* Wen-Fang Xu, Xiu-Li Guo and Yang Ou. Design, synthesis and biological activities of novel Ligustrazine derivatives. Bioorganic & Medicinal Chemistry 2007; 15(10): 3315–3320
Jingde Wu, Xinyong Liu *, Xianchao Cheng , Yuan Cao, Defeng Wang , Zhong Li, Wenfang Xu , Christophe Pannecouque , Myriam Witvrouw and Erik De Clercq. Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 2007, 12(8): 2003-2016.
Xin Yong LIU*, Ren Zhang YAN, Nian Gen CHEN, Wen Fang XU . Regioselective Synthesis and Anti-HIV Activity of the Novel 2- and 4-Substituted Pyrazolo[4,5-e][1,2,4]thiadiazines. Chin. Chem. Lett. 2007;18: 137-140
Xin-Yong Liu*, Xian-Jun Qu, Wei Tang. China-Japan enhance joint research cooperation for drug discoveries and development: News from CJMWDDT 2007 in Jinan, China. Drug Discov Ther 2007;1(1):1
2006
Xinyong Liu* Niangen Chen, Renzhang Yan, Wenfang Xu, Maria Teresa Molina, and Salvador Vega Regioselective Synthesis of the Novel N4-Substituted Pyrazolo[4,5-e][1,2,4] thiadiazines as Potent HIV-1 NNRTIs. Heterocycles, 2006; 68(6): pp.1225-1232
Xinyong Liu*, Renzhang Yan, Niangen Chen, Wenfang Xu, Maria Teresa Molina and Salvador Vega. Regioselective Synthesis of Novel N2- and N4-Substituted 7-Methylpyrazolo [4,5-e] [1,2,4]thiadiazines, Molecules, 2006, 11: 827-836
Xianchao Cheng, Xinyong Liu*, Wenfang Xu. Synthesis of Novel Ligustrazine Derivatives as Potential Platelet Aggregation Inhibitors. Chinese Chemical Letters 2006; Vol. 17, No. 10, pp 1317-1320
Xian-chao Cheng, Xin-yong Liu* and Wen-fang Xu .The preparation of novel ligustrazine derivatives as potential cerebrocardiac vascular agents. Journal of Chemical Research, 2006; September, 577–579
Ren-Zhang Yan, Xin-Yong Liu*, Wen-Fang Xu, Christophe Pannecouque1, Myriam Witvrouw, and Erik De Clercq. Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4,5-e][1, 2, 4]thiadiazines. Arch Pharm Res, 2006; 29, No 11, 957-962
2005-2003
Xinyong Liu*, Niangen Chen, Yinzhang Yan, Wen-fang Xu. Design and Synthesis of N4-Substituted Pyrazolo[4,5-e][1,2,4] Thiadiazine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Chinese Journal of Organic Chemistry. 2005; Vol. 25, Suppl., 701
Xianchao Cheng, Xinyong Liu* Wenfang Xu. Recent advances in the structural modification of ligustrazine; cerebro- and cardiovascular activity of ligustrazine derivatives. Drugs of the Future, 2005; 30(10): 1059.
Xin Yong Liu*, Wen Fang Xu, Jing De Wu. Synthesis of 4-Amino-5-furyl-2-yl-4H-1, 2, 4-triazole-3-thiol Derivatives as a Novel Class of Endothelin(ET) Receptor Antagonists. Chin Chem. Letter (CCL); 2003, 14(8):790-793
Zeng Bao-Shan, Chen Min-Bo*, Dong Xi-Cheng, Liu Xin-Yong*. q2 Guided Conformation Selection Approach of CoM FA for HIV-1 RT Inhibitors. Acta Chemica Sinica, 2003; 61(7): 1121-1128
Xinyong Liu*, Zhang Rui and Wenfang Xu. Synthesis of The Novel Liqustrazine Derivatives and Their Protective Effect on Injured Vascular Endothelial Cell Damaged by Hydrogen Peroxide. Bioorg. Med. Chem. Letter; 2003; 13: 2123-2126
|
